Nascent Pharma Holdings (NASC) AI Stock Analysis

• Market Cap: $1.44M
• Dividend Yield: N/A
• Average Volume (3M): 35.25K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.37
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 75,841,990
• 10 Day Avg. Volume: 42,355
• 30 Day Avg. Volume: 35,253
• PEG Ratio: <0.01
• Price to Book (P/B): -0.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.39
• Enterprise Value/Market Cap: 6.72
• Enterprise Value/Revenue: 9.37
• Enterprise Value/Gross Profit: -6.09
• Enterprise Value/Ebitda: -0.97
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

No summary available

Positive Factors

Industry Trends

Favorable industry trends, such as increased legalization and consumer interest, provide a supportive backdrop for Can B's growth and market penetration efforts.

Product Diversification

A broad product portfolio allows Can B to capture diverse consumer preferences, reducing dependency on a single product line and enhancing resilience against market fluctuations.

Market Expansion

Strategic partnerships enhance Can B's market presence, enabling broader distribution and access to new customer segments, supporting long-term revenue growth.

Negative Factors

Revenue Decline

Declining revenue trends indicate potential market share loss and operational inefficiencies, challenging Can B's growth prospects and competitive positioning.

Profitability Challenges

Ongoing profitability issues hinder Can B's ability to generate sustainable earnings, affecting long-term viability and shareholder value creation.

Financial Health

Negative equity and insolvency risks undermine Can B's financial stability, limiting its ability to invest in growth opportunities and weather economic downturns.

Nascent Pharma Holdings Business Overview & Revenue Model

Company Description

Nascent Pharma Holdings, Inc. engages in the protection and commercialization of cannabis patents. It produces superfood drink mix products under the Longevity brand name. The company was formerly known as Can B Corp. and changed its name to Nascent Pharma Holdings, Inc. in September 2025. Nascent Pharma Holdings, Inc. was incorporated in 2005 and is based in Hicksville, New York.

How the Company Makes Money

Can B Corp generates revenue primarily through the sale of its hemp-derived products, which are distributed both through direct-to-consumer channels and wholesale distribution networks. The company leverages e-commerce platforms to reach a broad customer base and enhance its market presence. Key revenue streams include the sale of CBD oils, topicals, and other hemp-based wellness products. Can B Corp also capitalizes on strategic partnerships with retailers and distributors to expand its reach in various markets. Additionally, the company may engage in private label and white label manufacturing for other brands, providing another avenue for revenue generation. Factors contributing to its earnings include the growing consumer interest in natural health alternatives and the legalization and increasing acceptance of hemp-derived products in various regions.

Nascent Pharma Holdings Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Mar 2021
Income Statement
Total Revenue	1.03M	0.00	2.16M	6.69M	4.60M	1.71M
Gross Profit	-1.59M	-742.32K	358.70K	2.61M	2.99M	1.43M
EBITDA	-9.99M	-7.65M	-5.82M	-12.59M	-9.52M	-7.16M
Net Income	-13.26M	-10.20M	-9.74M	-14.92M	-12.17M	-8.88M
Balance Sheet
Total Assets	1.86M	299.54K	10.13M	15.56M	16.47M	3.91M
Cash, Cash Equivalents and Short-Term Investments	7.88K	5.96K	34.01K	73.19K	449.00K	457.80K
Total Debt	9.01M	8.30M	9.18M	9.34M	7.28M	2.08M
Total Liabilities	11.64M	13.02M	11.13M	12.86M	10.86M	2.44M
Stockholders Equity	-9.79M	-12.72M	-1.00M	2.70M	5.62M	1.48M
Cash Flow
Free Cash Flow	246.61K	-221.63K	-1.32M	-3.95M	-8.04M	-2.00M
Operating Cash Flow	246.61K	-221.63K	-1.30M	-3.95M	-7.32M	-1.95M
Investing Cash Flow	-9.97K	231.32K	-84.63K	0.00	-860.79K	-25.25K
Financing Cash Flow	-259.94K	-27.82K	1.35M	3.57M	8.17M	2.38M

Nascent Pharma Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NASC, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.54 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NASC.

Nascent Pharma Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NASC	―	$1.44M	-0.06	―	―	―	―
RDHL	47 Neutral	$4.46M	-0.42	―	―	―	―
UPC	46 Neutral	$1.31M	>-0.01	2.66%	―	-27.81%	―
PRFX	44 Neutral	$1.79M	-0.13	―	―	―	―
CPHI	42 Neutral	$3.15M	-2.90	-43.00%	―	-26.92%	69.90%
SHPH	―	$4.95M	-0.84	-9999.00%	―	―	79.31%